CAS: 59729-32-7; (S)-1-(3-(Dimethylamino)Propyl)-1-(4-Fluorophenyl)-1,3-Dihydroisobenzofuran-5-Carbonitrile Hydrobromide

上下游产品

CAS号59729-33-8 西酞普兰 | CAS号103146-26-5 4-[4-(二甲氨基)-1-(... | CAS号64169-67-1 1-(4-氟苯基)-1,3-二... | CAS号109-54-6 3-氯-1-(N,N-二甲基)丙胺 | CAS号103146-25-4 4-(4-(二甲基氨基)-1-... | CAS号265137-39-1 4,4-dimethyl-2-... | CAS号10035-10-6 氢溴酸 | CAS号460-00-4 对氟溴苯 | CAS号352-13-6 4-氟苯基溴化镁 | CAS号5407-04-5 3-二甲氨基氯丙烷盐酸盐 | CAS号59729-33-8 西酞普兰 | CAS号64372-56-1 1-[3-(二甲基氨基)丙基]... | CAS号63284-72-0 艾司西酞普兰 E

Citalopram Oxalate置于氨,氢溴酸体系中,用 水,甲苯,丙酮 作为反应溶剂,化学反应生成 氢溴酸西酞普兰
参考文献:Preparation Of Pure Citalopram
标题:Preparation Of Pure Citalopram
摘要:本发明涉及一种在工业上具有优势的西酞普兰(化学式i)纯化方法,其中存在于粗西酞普兰中作为杂质的去甲基西酞普兰(化学式ii)被甲基化以产生纯净的西酞普兰.所得的西酞普兰产品被分离为其碱性形式或药用可接受的盐.

专利信息

专利号:US-2008119662-A1
优先权日:2004-02-16
标 题:One Spot Synthesis of Citalopram from 5-Cyanophthalide
发明人：NARAHARI BABU AMBATI; SRINIVAS GOUD VUDDAMARI; GAONKAR SANTOSH LAXMAN; MANJUNATHA SULUR G; KULKARNI ASHOK KRISHNA; KULKARNI MADHARI A
权利人:JUBILANT ORGANOSYS LIMTED
摘要:A process for one pot synthesis of citalopram is disclosed. The process comprises subjecting 5-cyano phthalide to Grignard reduction followed cyclization and followed by C-alkylation reaction to obtain citalopram without isolation and purification of any intermediates. In another embodiment, 5-cyano phthalide is subjected to sequential Grignard reactions followed by cyclization to obtain citalopram without isolation and purification of any intermediate stages.

专利号:US-2006030625-A1
优先权日:2004-08-06
标 题 :Dietary neurotransmitter precursors for balanced synthesis of neurotransmitters
发明人：HART CHERYLE RAM; GROSSMAN RONALD S; RAM HERBERT
权利人:HART CHERYLE RAM; GROSSMAN RONALD S; RAM HERBERT
摘要:Dietary supplements for treating a neurotransmitter deficiency include one or more precursors of the deficient neurotransmitter and a cofactor for activating in vivo enzymatic synthesis of the deficient neurotransmitter. The dietary supplements can also include an appropriate neurotransmitter, such as an amino acid. When administered through the oral mucosa, increases in levels of the deficient neurotransmitters and relief from deficiency symptoms are obtained.

专利号:US-7166729-B2
优先权日:2001-08-02
标 题:Process for the preparation of 5-substituted isobenzofurans
发明人：DALL ASTA LEONE; COTTICELLI GIOVANNI
权利人:INFOSINT SA
摘要:There is described a process for the preparation of citalopram and of its pharmaceutically acceptable salts, which comprises treating a 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5 isobenzofurancarbaldoxime, O-substituted preferably with a diphenylmethyl or triphenylmethyl group, with formic-acetic anhydride. Furthermore, the total synthesis of citalopram, as free base or in form of its pharmaceutically acceptable salt, starting from 5-formylphthalide is described.

专利号:US-8815883-B2
优先权日:2009-11-02
标 题 :Compounds and methods for inhibiting serotonin synthesis
发明人：LANDRY DONALD; DENG SHI-XIAN
权利人:LANDRY DONALD; DENG SHI-XIAN; TRUSTEES OF COLUMBIA UNVIERSITY IN THE CITY OF NEW YORK
摘要:Compounds having the structures below that are TPH1 inhibitors are provided: The compounds are useful of, e.g., to increase bone mass. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis.

专利号:US-12201669-B2
优先权日:2021-03-11
标 题:Small molecule suppressors of APOE gene expression and cerebral vascular amyloid pathology
发明人：TSAI LI-HUEI; BLANCHARD JOEL
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:The present disclosure provides methods of inhibiting amyloid synthesis in a subject using small molecule inhibitors. The invention also includes methods of treating disease associated with amyloid synthesis, such as Alzheimer's disease. The small molecule inhibitors disclosed herein are compounds which are non-immunosuppressant cyclosporin including the pharmaceutically acceptable salts thereof.

专利号:WO-2025019775-A1
优先权日:2023-07-19
标题 :Endoxifen compositions and methods of use thereof and synthesis thereof
发明人：QUAY STEVEN
权利人:ATOSSA THERAPEUTICS INC
摘要:Described herein are endoxifen compositions comprising novel compounds and methods of use thereof. Methods of synthesis for the compositions are described herein. The endoxifen compositions described herein may exhibit aromatase inhibition activity or estrogen receptor activity. The endoxifen compositions described herein may be useful in the treatment of a condition in a subject, such as cancer.